Strategic Financial Concepts LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,958 shares of the life sciences company's stock, valued at approximately $1,464,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. Private Trust Co. NA increased its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. Focused Wealth Management Inc bought a new stake in shares of Illumina during the third quarter valued at approximately $63,000. Finally, Hollencrest Capital Management bought a new stake in shares of Illumina during the third quarter valued at approximately $63,000. Institutional investors own 89.42% of the company's stock.
Illumina Price Performance
NASDAQ ILMN traded down $1.54 on Friday, reaching $100.24. The company had a trading volume of 3,135,782 shares, compared to its average volume of 2,405,156. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. The firm's 50 day moving average price is $133.56 and its 200 day moving average price is $134.88. Illumina, Inc. has a 12 month low of $99.35 and a 12 month high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. As a group, equities analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.
Wall Street Analyst Weigh In
ILMN has been the subject of a number of research analyst reports. Barclays downgraded shares of Illumina from an "equal weight" rating to an "underweight" rating and cut their target price for the stock from $130.00 to $100.00 in a research report on Monday. HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Canaccord Genuity Group cut their target price on shares of Illumina from $145.00 to $135.00 and set a "hold" rating for the company in a research report on Friday, February 7th. Citigroup downgraded shares of Illumina from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Guggenheim cut their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has an average rating of "Moderate Buy" and an average price target of $159.45.
Read Our Latest Report on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
